Business Context and Reporting Period
DexCom, Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. The company designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management. Key product milestones include the launch of the Stelo biosensor in August 2024 and FDA clearance for the Dexcom G7 15-Day CGM System in April 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $1,036.0 million | $921.0 million |
| Gross Profit | $589.0 million | $561.9 million |
| Gross Margin | 56.9% | 61.0% |
| Operating Income | $133.7 million | $101.1 million |
| Net Income | $105.4 million | $146.4 million |
| Diluted EPS | $0.27 | $0.36 |
| Operating Cash Flow | $183.8 million | $209.2 million |
| Cash & Short-Term Investments | $2.70 billion | $2.58 billion (Dec 31, 2024) |
| Debt (Senior Convertible Notes) | $2.46 billion (Carrying Value) | $2.44 billion |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 12% year-over-year, driven by a net addition of approximately 500,000 to 600,000 customers in 2024. Growth was partially offset by pricing headwinds and channel mix changes.
- Margin Compression: Gross margin declined to 56.9% from 61.0% due to supply chain inefficiencies, lower production yields, and product mix shifts.
- Net Income Decline: Net income decreased 28% to $105.4 million. This was primarily due to a higher effective tax rate (31.7% vs. a benefit in the prior year) driven by share-based compensation shortfalls and the absence of a discrete tax benefit from a Verily milestone payment recorded in Q1 2024.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 3% due to a $22.7 million reduction in legal expenses following the settlement of a patent infringement lawsuit in December 2024. R&D expenses increased 3% due to headcount growth.
Outlook, Risks, and Unusual Items
- Share Repurchase Program: In April 2025, the Board authorized a new $750.0 million share repurchase program, effective through June 30, 2026.
- Regulatory Risk (FDA Warning Letter): In March 2025, DexCom received an FDA warning letter regarding deficiencies in its quality management system and manufacturing processes at facilities in San Diego and Mesa. While the letter does not currently restrict product sales, failure to resolve these issues could lead to recalls, production shutdowns, or fines.
- Litigation: The company is defending against consolidated securities class action litigation and derivative lawsuits alleging false statements regarding 2024 revenue expectations. The company filed a motion to dismiss in March 2025.
- Debt Maturity: $1.21 billion in Senior Convertible Notes are due in November 2025. These are classified as current liabilities but may be converted to equity or cash prior to maturity depending on stock price conditions.
Investor Verification Checklist
- FDA Resolution: Monitor the status of the corrective action plan submitted in response to the March 2025 FDA warning letter.
- Margin Recovery: Verify if gross margins stabilize in Q2 2025 as production yield and supply chain issues are resolved.
- Debt Conversion: Assess the likelihood of the 2025 Convertible Notes being converted to equity versus requiring cash repayment at maturity in November 2025.
- Legal Outcomes: Track the court's ruling on the motion to dismiss the securities class action litigation.
- Stelo Adoption: Evaluate the revenue contribution and customer adoption rates of the Stelo over-the-counter biosensor.